240 related articles for article (PubMed ID: 24997576)
1. Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
Kigondu EM; Wasuna A; Warner DF; Chibale K
Bioorg Med Chem; 2014 Aug; 22(16):4453-61. PubMed ID: 24997576
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility of Mycobacterium tuberculosis to fusidic acid.
Cicek-Saydam C; Cavusoglu C; Burhanoglu D; Hilmioglu S; Ozkalay N; Bilgic A
Clin Microbiol Infect; 2001 Dec; 7(12):700-2. PubMed ID: 11843915
[TBL] [Abstract][Full Text] [Related]
4. Repurposed drug candidates for antituberculosis therapy.
An Q; Li C; Chen Y; Deng Y; Yang T; Luo Y
Eur J Med Chem; 2020 Apr; 192():112175. PubMed ID: 32126450
[TBL] [Abstract][Full Text] [Related]
5. Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization - Insight from DFT calculations, molecular docking and molecular dynamics simulations.
Akinpelu OI; Lawal MM; Kumalo HM; Mhlongo NN
Tuberculosis (Edinb); 2020 Mar; 121():101920. PubMed ID: 32279872
[TBL] [Abstract][Full Text] [Related]
6. New tuberculosis drugs on the horizon.
Cole ST; Riccardi G
Curr Opin Microbiol; 2011 Oct; 14(5):570-6. PubMed ID: 21821466
[TBL] [Abstract][Full Text] [Related]
7. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
Manjunatha UH; Smith PW
Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
[TBL] [Abstract][Full Text] [Related]
8. Reactive dirty fragments: implications for tuberculosis drug discovery.
Gopal P; Dick T
Curr Opin Microbiol; 2014 Oct; 21():7-12. PubMed ID: 25078318
[TBL] [Abstract][Full Text] [Related]
9. Is repositioning of drugs a viable alternative in the treatment of tuberculosis?
Palomino JC; Martin A
J Antimicrob Chemother; 2013 Feb; 68(2):275-83. PubMed ID: 23075693
[TBL] [Abstract][Full Text] [Related]
10. Recognizing drug targets using evolutionary information: implications for repurposing FDA-approved drugs against Mycobacterium tuberculosis H37Rv.
Ramakrishnan G; Chandra NR; Srinivasan N
Mol Biosyst; 2015 Dec; 11(12):3316-31. PubMed ID: 26429199
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of novel drug targets in Mycobacterium tuberculosis.
Singh V; Mizrahi V
Drug Discov Today; 2017 Mar; 22(3):503-509. PubMed ID: 27649943
[TBL] [Abstract][Full Text] [Related]
12. Improving the tuberculosis drug development pipeline.
Evangelopoulos D; McHugh TD
Chem Biol Drug Des; 2015 Nov; 86(5):951-60. PubMed ID: 25772393
[TBL] [Abstract][Full Text] [Related]
13. Antituberculosis compounds from a deep-sea-derived fungus Aspergillus sp. SCSIO Ind09F01.
Luo X; Zhou X; Lin X; Qin X; Zhang T; Wang J; Tu Z; Yang B; Liao S; Tian Y; Pang X; Kaliyaperumal K; Li JL; Tao H; Liu Y
Nat Prod Res; 2017 Aug; 31(16):1958-1962. PubMed ID: 28068839
[TBL] [Abstract][Full Text] [Related]
14. Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents.
Cooper CB
J Med Chem; 2013 Oct; 56(20):7755-60. PubMed ID: 23927683
[TBL] [Abstract][Full Text] [Related]
15. Rv0684/
Singh V; Dziwornu GA; Mabhula A; Chibale K
ACS Infect Dis; 2021 Aug; 7(8):2437-2444. PubMed ID: 34196521
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the research of heterocyclic compounds as antitubercular agents.
Yan M; Ma S
ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
[TBL] [Abstract][Full Text] [Related]
18. Target discovery focused approaches to overcome bottlenecks in the exploitation of antimycobacterial natural products.
Baptista R; Bhowmick S; Nash RJ; Baillie L; Mur LA
Future Med Chem; 2018 Apr; 10(7):811-822. PubMed ID: 29569936
[TBL] [Abstract][Full Text] [Related]
19. [Antituberculous action of a new antibiotic, Lividomycin. Effect on experimental tuberculosis of mice and cross resistance with other antituberculous agents].
Tsukamura M; Mizuno S; Yamamoto M
Kekkaku; 1970 Aug; 45(8):263-72. PubMed ID: 4989999
[No Abstract] [Full Text] [Related]
20. Structure-activity relationship analyses of fusidic acid derivatives highlight crucial role of the C-21 carboxylic acid moiety to its anti-mycobacterial activity.
Singh K; Kaur G; Shanika PS; Dziwornu GA; Okombo J; Chibale K
Bioorg Med Chem; 2020 Jul; 28(13):115530. PubMed ID: 32362386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
